Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

News & Events

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 7 November 2022

    ORYZON announces oral data presentation at the upcoming 64th American Society of Hematology annual conference

  • 4 November 2022

    ORYZON to give updates on corporate progress in November

  • 2 November 2022

    ORYZON reports results and corporate update for quarter ended September 30, 2022

  • 3 October 2022

    ORYZON to give updates on corporate progress in October

  • 16 September 2022

    ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

  • 8 September 2022

    ORYZON to give updates on corporate progress in September

  • 26 July 2022

    ORYZON collaborates with the CMT Research Foundation in the US

  • 22 July 2022

    ORYZON reports results and corporate update for half-year ending June 30, 2022

  • 19 July 2022

    ORYZON enters cooperative research and development agreement (CRADA) with U.S. National Cancer Institute to develop iadademstat in different cancers

  • 5 July 2022

    ORYZON announces a New Financing through a Convertible Bond Program for a Total amount up to €20 Million over 30 months

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy